In a regulatory filing, Viking Therapeutics disclosed that its CEO Brian Lian sold 45K shares of common stock on May 1st in a total transaction size of $1.01M.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on VKTX:
- Viking Therapeutics price target raised to $33 from $21 at H.C. Wainwright
- Viking Therapeutics reports Q1 EPS (25c), consensus (24c)
- Viking Therapeutics price target raised to $35 from $30 at Oppenheimer
- Viking Therapeutics call volume above normal and directionally bullish
- Viking Therapeutics 17.242M share Spot Secondary priced at $14.50
